Life Science Investing Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024
Life Science Investing Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH
Life Science Investing Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
Life Science Investing Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024
Brunswick Exploration Drills 36 Meters at 1.51% and Continues to Extend the Mineralized Footprint of Mirage
